Newsroom | 45325 results

WASHINGTON--(BUSINESS WIRE)--Amida launches TorQE, a pre-submission Medicaid data validation platform for T-MSIS data, reducing reactive remediation for state agencies....

SAN FRANCISCO--(BUSINESS WIRE)--Everfit, the leading fitness and wellness coaching platform, launched MacroSnap, its AI-powered meal scanner and macro tracker for coaches and clients. MacroSnap uses Everfit’s artificial intelligence to identify food items and calculate macronutrients from photos. Clients can snap a meal, scan a product barcode, or submit a photo of a nutrition label to log macronutrients in seconds. For coaches, all client nutrition data appears in real time on their Everfit da...

OKLAHOMA CITY--(BUSINESS WIRE)--Cytovance Biologics, a leading US-based contract development and manufacturing organization (CDMO) serving the biopharmaceutical industry, today announced the expansion of its upstream process development offerings with the addition of perfusion capabilities. The new capability provides biopharmaceutical companies with an additional process development option alongside traditional fed-batch manufacturing, enabling Cytovance to better support programs requiring hi...

NEW YORK--(BUSINESS WIRE)--Ash, a leading provider of white-label at-home health testing and care delivery, today announced two additions to its leadership team. Jon Stout has joined Ash's Board of Directors, and Matt Benton has joined as Chief Financial Officer. The appointments add proven operating and financial leadership as Ash rapidly accelerates its work with Medicare Advantage plans nationwide. Jon Stout Joins Board of Directors Stout is President of Motivo Health, a clinical supervision...

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its second quarter 2026 financial results on Wednesday, August 5, 2026, before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referenc...

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced positive topline results from its open-label Phase 2 clinical trial (Study ‘207’) evaluating VDPHL01, a proprietary extended-release oral minoxidil formulation, in females with mild-to-moderate pattern hair loss. VDPHL01 has the potential to become the first FDA-approved oral...

NEW YORK--(BUSINESS WIRE)--Clearside Biomedical, Inc. (“Clearside” or the “Company”) today announced that it has completed its financial restructuring and emerged from Chapter 11. All conditions to the effectiveness of the Company’s plan of reorganization (the “Plan”), as confirmed by the United States Bankruptcy Court for the District of Delaware, have been satisfied or waived, and the Plan became effective on the closing date. The Plan was sponsored by Steel Partners, Ltd. (“Steel Partners”),...

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced it will host an investor call and live webcast on Wednesday, July 15, 2026 at 8:00 am ET to review results from female treatment arms of the Phase 2 open-label Study ‘207’ evaluating VDPHL01, a proprietary extended-release oral minoxidil tablet, in males and females with mild-...

TYLER, Texas--(BUSINESS WIRE)--SynergenX, the largest provider of both in-clinic and telemedicine hormone optimization services, continued its strategic growth with the opening of its newest clinic in Tyler, expanding access to personalized, provider-led hormone optimization and wellness care for East Texas residents. The new location reflects SynergenX's continued investment in meeting the growing demand for comprehensive wellness services. The Tyler clinic offers testosterone replacement ther...

IRVINE, Californie et AMSTERDAM--(BUSINESS WIRE)--Agendia®, Inc., leader dans le domaine de l’oncologie de précision pour le cancer du sein, a annoncé aujourd’hui la décision officielle de l’Office fédéral de la santé publique (OFSP) d’accorder une prise en charge définitive et obligatoire par l’assurance maladie (Obligatorische Krankenpflegeversicherung, ou OKP) des tests d’expression multigénique, y compris MammaPrint®, pour les patientes éligibles atteintes d’un cancer du sein à un stade pré...